登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
ClinicalTrials.gov 上登记的一项重症肌无力开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07622342,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Male and female participants aged 18-75 years, confirmed diagnosis of generalized myasthenia gravis (gMG) (Myasthenia Gravis Foundation of America [MGFA] class II-IV).
入选标准第 1 条
Myasthenic crisis (MGFA Class V) within 3 months prior to randomization;
排除标准第 4 条
Anti-CD20 monoclonal antibody within 6 months prior to randomization; other B-cell or plasma cell-depleting therapy within 6-12 months prior to randomization;
排除标准第 10 条
Any infection requiring hospitalization and/or intravenous antimicrobial therapy within 8 weeks prior to randomization, or any infection requiring oral antimicrobial therapy within 2 weeks prior to randomization;
排除标准第 23 条
Major surgery within 3 months prior to the screening, or planned major surgery during the study;
排除标准第 29 条
A history of malignancy within 5 years prior to screening;
排除标准第 17 条
Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody, treponemal pallidum antibody, or human immunodeficiency virus (HIV) antibody; for patients with HBsAg-negative but hepatitis B core antibody (HBcAb)-positive, regardless of the status of hepatitis B surface antibody (HBsAb), HBV-DNA testing is required to confirm their condition, with HBV-DNA-positive patients excluded and HBV-DNA-negative patients eligible to participate in the study.
排除标准第 24 条
Female subjects with fertility or male participants whose partners are women of childbearing age must avoid donating sperm/eggs from the date of signing the ICF until 12 weeks after the last study medication, and agree to take contraceptive measures as specified in the protocol
入选标准第 8 条
Pregnant or lactating females;
排除标准第 26 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07622342,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Male and female participants aged 18-75 years, confirmed diagnosis of generalized myasthenia gravis (gMG) (Myasthenia Gravis Foundation of America [MGFA] class II-IV). Positive for anti-AChR antibody or anti-MuSK antibody. MG-ADL total score ≥5 at screening and baseline, with >50% of the score attributable to non-ocular items. QMG score ≥11 at screening and baseline. Maintenance on stable standard of care (SOC) therapy. No contraindication to at least one rescue therapy: IVIg or PLEX. Provided written informed consent (ICF) after full understanding of the study content, procedures, and potential adverse reactions. Female subjects with fertility or male participants whose partners are women of childbearing age must avoid donating sperm/eggs from the date of signing the ICF until 12 weeks after the last study medication, and agree to take contraceptive measures as specified in the protocol排除标准:Exclusion Criteria:
Presence of any of the following medical histories or comorbidities: Any untreated thymic epithelial tumor, mediastinal germ cell tumor, or other malignant mediastinal mass; or any thymic cyst or other mass requiring immediate intervention per investigator judgment; Previous history of thymic tumor not meeting protocol requirements; Myasthenic crisis (MGFA Class V) within 3 months prior to randomization; Any known disease other than gMG that may interfere with study procedures and assessments; A history of progressive multifocal leukoencephalopathy (PML); A history of body irradiation or organ transplantation. Use of any of the following drugs/treatments or participation in a clinical study: Prior treatment with CAR-T or other cellular therapy, or T-cell engager (TCE) therapy; Anti-CD20 monoclonal antibody within 6 months prior to randomization; other B-cell or plasma cell-depleting therapy within 6-12 months prior to randomization; Alkylating agent within 12 weeks prior to randomization; Any biologic for MG treatment within 12 weeks prior to randomization; Neonatal Fc receptor antagonist therapy within 8 weeks prior to randomization; Janus kinase (JAK), Bruton tyrosine kinase (BTK), or tyrosine kinase 2 (TYK2) inhibitor within 12 weeks prior to randomization; IVIg, subcutaneous immunoglobulin, or PLEX therapy within 4 weeks prior to randomization; Live/attenuated live vaccine within 4 weeks prior to randomization, or planned vaccination during the study. A history of malignancy within 5 years prior to screening; Infection-related medical history and examinations: A history of herpes zoster meeting any of the following: 1) A history of disseminated herpes zoster, herpes zoster encephalitis, or ocular herpes zoster involving the retina; 2) Recurrent herpes zoster with 2 or more episodes within 2 years; 3) Herpes zoster infection not fully resolved within 12 weeks prior to screening; A history of tuberculosis (TB) or latent TB infection; A known history of primary immunodeficiency, splenectomy, or any underlying condition predisposing to infection; A history of recurrent infections requiring hospitalization and intravenous antibiotics; Any infection requiring hospitalization and/or intravenous antimicrobial therapy within 8 weeks prior to randomization, or any infection requiring oral antimicrobial therapy within 2 weeks prior to randomization; Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody, treponemal pallidum antibody, or human immunodeficiency virus (HIV) antibody; for patients with HBsAg-negative but hepatitis B core antibody (HBcAb)-positive, regardless of the status of hepatitis B surface antibody (HBsAb), HBV-DNA testing is required to confirm their condition, with HBV-DNA-positive patients excluded and HBV-DNA-negative patients eligible to participate in the study. General situation: Pregnant or lactating females; A history of alcohol abuse or illicit drug abuse within 1 year prior to screening; A history of allergic diathesis, or known hypersensitivity/intolerance to any component of the investigational product; Major surgery within 3 months prior to the screening, or planned major surgery during the study; Any condition that, in the investigator's judgment, may affect evaluation of study drug safety and efficacy, or any other condition that renders the subject ineligible.
引自 ClinicalTrials.gov, NCT07622342, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07622342,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。